CombiCTx: Screening diffusion gradients of anti-cancer drug combinations
Preprint
Abstract
The reduced effectiveness of chemotherapy in many patients highlights the need for novel drug combinations and optimal ratios that target multiple survival mechanisms, which tumors may engage to confer drug resistance. Dynamic conditions within the tumor microenvironment shape cell behavior and influence the response to anti-cancer drugs, varying by cell type and local context. Accordingly, assays that identify effective concentrations and drug interactions (additive, synergistic, or antagonistic) in a relevant tumor tissue model are required to discover new combination treatments. To address this need for combinatorial chemotherapeutic (CTx) screening assays, we reconfigured CombiANT, a device for testing antibiotic interactions, and present a new assay called CombiCTx. The assay uses a device with three reservoirs containing gels loaded with chemotherapeutics or other anti-cancer drugs. The drug-loaded device is inverted and placed in a standard culture dish containing cancer cells, and both are then enclosed in gel. As drugs diffuse from the reservoirs, cancer cells are exposed to overlapping dynamic gradients of anti-cancer drugs, which can interact in various ways. We imaged doxorubicin diffusion in the assay using timelapse microscopy and employed the apoptotic agent staurosporine as a model drug, and established an imaging protocol for quantifying MDA-MB-231 breast cancer cell apoptosis along drug diffusion gradients. Finally, we tested navitoclax and gemcitabine to demonstrate the capacity of CombiCTx to evaluate combined cytotoxic effects while accounting for drug diffusion. Evaluating drug combinations with an assay that accounts for drug properties that influence diffusion in a complex tumor matrix may provide clinically relevant information.Keywords
All Related Versions
- Published version: Lab on a Chip, 26 (3), 695.
This publication has 57 references indexed in Scilit:
- Quantitative imaging of doxorubicin diffusion and cellular uptake in biomimetic gels with human liver tumor cellsDrug Delivery and Translational Research, 2023
- Fibrosis in tissue engineering and regenerative medicine: treat or trigger?Advanced Drug Delivery Reviews, 2019
- Analysis of drug combinations: current methodological landscapePharmacology Research & Perspectives, 2015
- A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumorsInvestigational New Drugs, 2014
- Fluorescent Probes2013
- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Selective Filtering of Particles by the Extracellular Matrix: An Electrostatic BandpassBiophysical Journal, 2009
- Induction of a Common Pathway of Apoptosis by StaurosporineExperimental Cell Research, 1994
- Self-Association of Doxorubicin and Related Compounds in Aqueous SolutionJournal of Pharmaceutical Sciences, 1984